Breda Genetics

What Breda Genetics does

Breda Genetics is an Italian clinical genomics company founded in 2015 and headquartered in Brescia, operating a fully equipped genomic laboratory accredited by the Region of Lombardy (Structure n. 1547 – Lab code 098352) and listed in the NCBI Genetic Testing Registry. It provides end-to-end clinical genomic testing — Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), targeted gene panels (An-yCAP), RNA sequencing, and newborn screening — integrated with internally developed AI-supported bioinformatics and phenotype-guided clinical interpretation. The portfolio is anchored by EXOME ULTRA-FAST, delivering FASTQ data in 3 working days and a medical report in 5 working days for NICU and prenatal cases, and by a sequencing-only FASTQ delivery service for laboratory partners.

The company serves four customer groups: hospitals and clinical institutions, diagnostic and research laboratories, individual patients and referring physicians, and public-health entities running newborn screening programs. It monetizes through per-test, quote-based pricing across clinical testing, sequencing-only FASTQ delivery, genetic counseling, and managed-services contracts for outsourced diagnostics and screening programs. Sample logistics are coordinated internationally via express courier, with free shipping from Italy and the EU for orders at or above €1,000. International referrals span more than 20 countries across Europe, the Middle East, and Latin America, supported by named institutional partners including Ospedale Infantile Regina Margherita, Fondazione IRCCS Istituto Neurologico Carlo Besta, Sultan Qaboos University Hospital, and Biotecgen SA.

The operating model is a hybrid of enterprise field sales for institutional partners, a PREMIUM direct-to-patient pathway with online genetic counseling, and a self-serve sequencing-only portal for registered laboratories. Technology differentiation rests on internally developed AI-based bioinformatics tools, integrated CNV detection from WES/WGS data, digital order management, and cloud-based genomic workflow management. Disclosed firmographics indicate 1–10 employees, and the company is a privately held single-member srl with €10,000 share capital and no evidence of external venture or private-equity backing — characterizing a lean, specialist clinical operation focused on interpretation quality and partnership-driven scale rather than high-volume lab throughput.

Name

Breda Genetics

Legal name

Breda Genetics srl

Website

https://bredagenetics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Breda Genetics is an Italian clinical genomics company providing accredited WES, WGS, panel, and newborn screening services to hospitals, diagnostic laboratories, and patients across more than 20 countries, with integrated AI-supported bioinformatics and clinical interpretation.

Ownership category

akta.pro rank

Product category

Clinical Genomics Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Clinical genetic testing
• Whole exome sequencing
• Whole genome sequencing
• Clinical genomics services
• Rare disease diagnostics

Headquarters

HQ city

Brescia

HQ country

Italy

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Genetic Testing Services: End-to-end clinical genomic testing services including Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), and targeted gene panels, with full service covering sample processing, sequencing, bioinformatics, clinical interpretation, and medical reporting. Revenue is generated on a per-test basis, with pricing varying by test type, urgency, and whether interpretation is included.
2. Sequencing-Only Services: Sequencing-only model delivering FASTQ data to laboratories and research institutions with optional bioinformatics support. Targeted at partner laboratories that perform their own clinical interpretation. Revenue generated per sample on a unit pricing basis.
3. Genetic Counseling Services: Pre- and post-test genetic counseling integrated into the clinical service offering, supporting diagnostic pathways for patients and enabling clinician decision-making. May be bundled with genomic testing services or offered as a standalone consultation.
4. Industrial Genomics / Laboratory Services: Outsourced genomic testing services for hospitals and diagnostic laboratories, including accredited diagnostic testing and scalable genomic programs such as newborn screening. Revenue derived from service contracts and per-sample pricing for diagnostic and screening programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

Breda Genetics operates a clinical genomic laboratory providing end-to-end genetic testing services, including Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), targeted gene panels, and newborn screening programs. Services combine wet-lab sequencing, proprietary AI-supported bioinformatics, expert phenotype-guided clinical interpretation, and accredited medical reporting. The company serves both institutional clients (hospitals, diagnostic laboratories, research institutions) through its Industrial Genomics division and individual patients/physicians through its PREMIUM clinical pathway.

Product overview

Breda Genetics is a clinical genomics company offering end-to-end genetic testing services — from wet lab processing through bioinformatics and clinical reporting — within a fully integrated clinical framework. The company operates a dedicated and fully equipped genomic laboratory designed to meet clinical standards and accreditation requirements. The core product portfolio centers on three main sequencing modalities: Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), and targeted Panel Testing (An-yCAP), each available in different configurations (singleton, trio, ultra-fast). These are complemented by specialized services including Sequencing-only (FASTQ delivery for partner labs), Newborn Screening programs, Genetic Counseling, and Predictive Genomics (EXOME PRO/GENOME PRO). The company serves both individual patients through PREMIUM pathways and institutional clients (hospitals, laboratories) through Industrial Genomics services.

Differentiator

Problem solved

Functional benefit

Products and services

• Whole Exome Sequencing (WES) Analysis of the protein-coding regions of the genome (~20,000 genes and mitochondrial DNA), used for diagnosis of rare genetic diseases as first-line or complex diagnostic testing for clinicians, hospitals, and patients with unresolved cases.
• Whole Genome Sequencing (WGS) Analysis of coding and non-coding regions of the genome, providing comprehensive genomic coverage for complex clinical cases or undiagnosed conditions.
• Panel Testing (An-yCAP) Targeted analysis of selected gene sets for specific clinical indications, with flexible exome-based panels that can be updated based on new gene-disease associations.
• Exome Ultra-Fast Rapid whole exome sequencing service delivering FASTQ data in 3 working days and medical report in 5 working days, designed for neonatal intensive care and urgent prenatal cases.
• Sequencing-Only (FASTQ Delivery) FASTQ delivery service for laboratories and research facilities with optional bioinformatics support, including standard turnaround (3-4 weeks) and ultra-fast workflows, designed for partner laboratories with in-house clinical interpretation capabilities.
• Genetic Counseling Pre- and post-test genetic counseling services integrated into the diagnostic pathway, available with online consultation for international patients and clinicians.
• Paternity Testing Genetic paternity testing service offered through the geneticist pathway.
• ART Genetic Pathway Assisted reproductive technology genetic pathway for reproductive genetic evaluation and recurrent miscarriage assessment.
• Newborn Screening Genomic screening workflows supporting regional and national newborn screening programs, based on experience with over 4,000 neonatal exomes.
• Exome Pro / Genome Pro Proactive/predictive genomic testing for healthy individuals seeking comprehensive genetic health insights.
• Industrial Genomics Services End-to-end clinical genomics services for hospitals and laboratories, including accredited diagnostics, bioinformatics, and clinical reporting for rare disease testing.

Quantifiable outcome

• Ultra-fast WES turnaround: FASTQ in 3 working days, medical report in 5 working days (vs. standard 3-4 weeks)
• +4 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and regional.

• Ospedale Infantile Regina Margherita (Torino, Italia)coreStrategic or Co-development PartnerMajor pediatric hospital in Turin, Italy. Breda Genetics has collaborated with this institution on complex genomic diagnostic cases, contributing to rare disease diagnosis and clinical genomic research.
• Italian Institute for Genomic Medicine (Torino, Italia)coreStrategic or Co-development PartnerLeading national institute dedicated to genomic medicine research and clinical application. Collaboration on genomic research and diagnostic projects in Italy.
• Sultan Qaboos University Hospital (Muscat, Oman)coreStrategic or Co-development PartnerMajor university hospital in the Sultanate of Oman. International collaboration for genomic diagnostic referrals, extending Breda Genetics' reach to the Middle East region.
• Fondazione IRCCS Istituto Neurologico Carlo Besta (Milano, Italy)coreStrategic or Co-development PartnerRenowned neurological research institute in Milan. Collaboration focused on neurological genomic cases, leveraging Breda Genetics' WES/WGS capabilities for complex neurogenetic disorders.
• Fondazione Telethon (Roma, Italia)coreStrategic or Co-development PartnerMajor Italian non-profit foundation dedicated to supporting research on genetic diseases. Collaboration supporting rare disease research and diagnostic capabilities.
• Biotecgen SA (Bogotá, Colombia)regionalChannel Partner/ Reseller/ DistributorColombian biotechnology company and laboratory partner in Latin America. Represents Breda Genetics' diagnostic services in the Colombian market, facilitating access to genomic testing for patients and clinicians in the region.
• Università di Firenze (Firenze, Italia)coreStrategic or Co-development PartnerUniversity of Florence in Italy. Academic collaboration for genomic research and diagnostic development, supporting academic research projects involving genomic analysis.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Blueprint Genetics: Blueprint Genetics offers targeted panels, WES, and clinical interpretation for hereditary disease, with strong rare-disease focus. Comparable in panel-plus-exome strategy, hospital/laboratory sales motion, and international customer base.
• MNG Laboratories (now part of Labcorp): MNG Laboratories provides clinical sequencing including WES, neurological panels, and rare-disease diagnostics. Comparable in clinical sequencing services with hospital/laboratory channel focus and neurological rare-disease expertise overlapping Besta collaborations.
• Dante Labs: Dante Labs offers WES, WGS, and direct-to-consumer/preventive genomics primarily through European channels. Comparable in offering WES/WGS with international patient reach, though with stronger direct-to-consumer positioning.
• Centogene: Centogene is a European-based clinical genomics laboratory offering WES, WGS, panels, and rare-disease diagnostics with international reach. Highly comparable in product mix, target customers (hospitals, labs, patients), and rare-disease positioning, though operating at significantly larger scale.
• GeneDx (formerly Sema4): GeneDx provides clinical exome and genome sequencing with strong rare-disease and pediatric focus. Direct competitor in clinical WES/WGS services with global hospital and patient channels, and substantially greater scale and capital backing.
• PreventionGenetics: PreventionGenetics is a US-based clinical DNA testing laboratory providing WES, WGS, and large gene panels with physician-direct ordering. Comparable in offering comprehensive clinical genomic testing with strong rare-disease and hereditary disease emphasis.

Emerging players

• 3billion: 3billion is a Korea-based clinical genomics company focused on rare-disease exome and genome interpretation using AI. Comparable in AI-augmented interpretation, rare-disease niche, and international service delivery model.

Broad incumbents

• Ambry Genetics: Ambry Genetics is an established US clinical genomics lab offering hereditary disease panels, exomes, and clinical interpretation. A larger incumbent with overlapping capabilities but a much broader portfolio and substantially deeper commercial footprint.
• Baylor Genetics: Baylor Genetics is a US clinical laboratory providing WES, WGS, panels, and prenatal diagnostics, with academic/research affiliation. Comparable in WES/WGS and prenatal offerings, and a recognized incumbent in clinical rare-disease genomics.

Regional players

• Eurofins Genoma: Eurofins Genoma is an Italian clinical genetics laboratory offering prenatal and clinical genetic testing. Comparable in being an Italian clinical genetics lab with prenatal and rare-disease focus, representing a direct regional competitor in Breda Genetics' home market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/bredagenetics
• LinkedInlinkedin.com/company/breda-genetics-s-r-l-
• Instagraminstagram.com/breda.genetics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breda Genetics